All trials analyzed the composite of 3 major adverse cardiovascular events (MACE), which included cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, except the lixisenatide study that considered 4-point MACE, which also included hospitalization for heart failure (Table 1).5764 Although all the studies with arGLP-1 have demonstrated cardiovascular safety (noninferiority vs
As emergency physicians, we need to understand these challenges and be familiar with their side effects, complications, or concerns related to their use/ availability
The decision to use L-carnitine alongside Mounjaro should always be made in consultation with your GP, diabetes specialist nurse, or endocrinologist
But the compounders havent given up: They also appealed the judges call on March 10, which keeps things legally fuzzy
Table of Contents: What are the FDA criteria for Semaglutide GLP-1